|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Adenoma, multiple endocrine |
|
Esophagitis, erosive |
|
Gastroesophageal Reflux Disease |
|
Hemorrhage, upper gastrointestinal, prophylaxis |
|
Mastocytosis, systemic |
|
Ulcer, duodenal |
|
Ulcer, gastric |
|
Zollinger- Ellison syndrome |
| |
|
|
SIDE EFFECTS:
|
|
acneiform rash |
|
agitation |
|
agranulocytosis |
|
anaphylactoid reactions |
|
angioedema |
|
anxiety |
|
arthralgia |
|
AV block |
|
bronchospasm |
|
confusion |
|
depression |
|
diarrhea |
|
dizziness |
|
elevated hepatic enzymes |
|
exfoliative dermatitis |
|
galactorrhea |
|
gynecomastia |
|
hallucinations |
|
headache |
|
hepatitis |
|
hyperprolactinemia |
|
impotence |
|
infection |
|
jaundice |
|
leukopenia |
|
libido decrease |
|
maculopapular rash |
|
myalgia |
|
neutropenia |
|
pancreatitis |
|
pancytopenia |
|
premature ventricular contractions (PVCs) |
|
sinus bradycardia |
|
sinus tachycardia |
|
Stevens-Johnson syndrome |
|
thrombocytopenia |
|
toxic epidermal necrolysis |
|
urticaria |
|
vasculitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
breast-feeding |
|
children |
|
elderly |
|
gastric cancer |
|
2-blocker*hypersensitivity#243"H2-blocker hypersensitivity |
|
hepatic disease |
|
immunosuppression |
|
infection |
|
intravenous administration |
|
pregnancy |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Duodenal ulcer-Treatment: Oral, 300 mg four times a day, with meals and at bedtime; 400 or 600 mg two times a day, in the morning and at bedtime; or 800 mg at bedtime.
Note: A 1600-mg dose of cimetidine at bedtime has been found to produce a more rapid healing in some ulcer patients who have an endoscopically demonstrated ulcer larger than 1 cm and are also heavy smokers.
Prophylaxis of recurrent duodenal ulcer: Oral, 300 mg two times a day, in the morning and at bedtime; or 400 mg at bedtime. Patients have been maintained on continued treatment with 400 mg at bedtime for periods of up to five years.
Gastric ulcer, benign, active-Oral, 300 mg four times a day, with meals and at bedtime; or 600 mg two times a day, in the morning and at bedtime; or 800 mg at bedtime.
Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 200 mg with water as symptoms occur; dose may be repeated once in twenty-four hours
Prophylaxis: Oral, 100 to 200 mg with water up to one hour before consuming food or beverages expected to cause symptoms
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 300 mg four times a day, with meals and at bedtime, the dosage being adjusted as needed, and therapy continued for as long as clinically indicated.
Gastroesophageal reflux-Oral, 800 to 1600 mg per day in divided doses for 12 weeks.
Upper gastrointestinal bleeding-Oral, 300 mg every six hours; or 600 mg two times a day, in the morning and at bedtime.
Note: For patients with impaired renal function-Oral, 300 mg every twelve hours, the dosage being increased to 300 mg every eight hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present. |
|
MAXIMUM ADULT DOSE:
|
|
Up to 2.4 grams daily ; however, doses up to 12 grams per day have been used in the treatment of pathological hypersecretory conditions.
|
|
PEDIATRIC DOSE:
|
|
Duodenal ulcer; or
Gastric ulcer-Oral, 20 to 40 mg per kg of body weight a day in divided doses four times a day, with meals and at bedtime.
Gastroesophageal reflux -Oral, 40 to 80 mg per kg of body weight a day in divided doses four times a day.
Note: In certain circumstances, doses may be titrated based on gastric pH.
Clinical experience with the use of cimetidine in children up to 16 years of age is limited; risk-benefit must be considered.
In children with impaired renal function, dosage should be reduced to 10 to 15 mg per kg of body weight a day, and the dosing interval increased to eight hours. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Duodenal ulcer-Treatment: Oral, 300 mg four times a day, with meals and at bedtime; 400 or 600 mg two times a day, in the morning and at bedtime; or 800 mg at bedtime.
Note: A 1600-mg dose of cimetidine at bedtime has been found to produce a more rapid healing in some ulcer patients who have an endoscopically demonstrated ulcer larger than 1 cm and are also heavy smokers.
Prophylaxis of recurrent duodenal ulcer: Oral, 300 mg two times a day, in the morning and at bedtime; or 400 mg at bedtime. Patients have been maintained on continued treatment with 400 mg at bedtime for periods of up to five years.
Gastric ulcer, benign, active-Oral, 300 mg four times a day, with meals and at bedtime; or 600 mg two times a day, in the morning and at bedtime; or 800 mg at bedtime.
Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 200 mg with water as symptoms occur; dose may be repeated once in twenty-four hours
Prophylaxis: Oral, 100 to 200 mg with water up to one hour before consuming food or beverages expected to cause symptoms
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 300 mg four times a day, with meals and at bedtime, the dosage being adjusted as needed, and therapy continued for as long as clinically indicated.
Gastroesophageal reflux-Oral, 800 to 1600 mg per day in divided doses for 12 weeks.
Upper gastrointestinal bleeding-Oral, 300 mg every six hours; or 600 mg two times a day, in the morning and at bedtime.
Note: For patients with impaired renal function-Oral, 300 mg every twelve hours, the dosage being increased to 300 mg every eight hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present. |
|
|
|
|
|